Indazole as a Privileged Scaffold: The Derivatives and their Therapeutic Applications

被引:26
作者
Qin, Jinling [2 ,3 ]
Cheng, Weyland [1 ]
Duan, Yong-Tao [1 ]
Yang, Hua [2 ,3 ]
Yao, Yongfang [1 ,2 ,3 ]
机构
[1] Zhengzhou Univ, Henan Prov Key Lab Childrens Genet & Metab Dis, Childrens Hosp, Zhengzhou 450018, Henan, Peoples R China
[2] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 450001, Henan, Peoples R China
[3] Zhengzhou Univ, Minist Educ China, Key Lab Adv Drug Preparat Technol, Zhengzhou 450001, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
Heterocyclic compound; indazole; therapeutic application; structure-activity relationship; pharmacology; activity;
D O I
10.2174/1871520620999200818160350
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Heterocyclic compounds, also called heterocycles, are a major class of organic chemical compound that plays a vital role in the metabolism of all living cells. The heterocyclic compound, indazole, has attracted more attention in recent years and is widely present in numerous commercially available drugs. Indazole-containing derivatives, representing one of the most important heterocycles in drug molecules, are endowed with a broad range of biological properties. Methods: A literature search was conducted in PubMed, Google Scholar and Web of Science regarding articles related to indazole and its therapeutic application. Results: The mechanism and structure-activity relationship of indazole and its derivatives were described. Based on their versatile biological activities, the compounds were divided into six groups: anti-inflammatory, antibacterial, anti-HIV, antiarrhythmic, antifungal and antitumour. At least 43 indazole-based therapeutic agents were found to be used in clinical application or clinical trials. Conclusion: This review is a guide for pharmacologists who are in search of valid preclinical/clinical drug compounds where the progress of approved marketed drugs containing indazole scaffold is examined from 1966 to the present day. Future direction involves more diverse bioactive moieties with indazole scaffold and greater insights into its mechanism.
引用
收藏
页码:839 / 860
页数:22
相关论文
共 189 条
  • [61] PHASE-II TRIAL OF PIROXANTRONE IN GASTRIC-CARCINOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    HANTEL, A
    TANGEN, C
    GLUCK, WL
    MACDONALD, JS
    [J]. INVESTIGATIONAL NEW DRUGS, 1994, 12 (02) : 159 - 161
  • [62] First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer
    He, Aiwu Ruth
    Cohen, Roger B.
    Denlinger, Crystal S.
    Sama, Ashwin
    Birnbaum, Ariel
    Hwang, Jimmy
    Sato, Takami
    Lewis, Nancy
    Mynderse, Michelle
    Niland, Michele
    Giles, Jennifer
    Wallin, Johan
    Moser, Brian
    Zhang, Wei
    Walgren, Richard
    Plimack, Elizabeth R.
    [J]. ONCOLOGIST, 2019, 24 (09) : E930 - E942
  • [63] The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo
    Heffeter, Petra
    Atil, Bihter
    Kryeziu, Kushtrim
    Groza, Diana
    Koellensperger, Gunda
    Koerner, Wilfried
    Jungwirth, Ute
    Mohr, Thomas
    Keppler, Bernhard K.
    Berger, Walter
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (15) : 3366 - 3375
  • [64] Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases
    Hemmerling, Martin
    Nilsson, Stinabritt
    Edman, Karl
    Eirefelt, Stefan
    Russell, Wayne
    Hendrickx, Ramon
    Johnsson, Eskil
    Mardh, Carina Karrman
    Berger, Markus
    Rehwinkel, Hartmut
    Abrahamsson, Anna
    Dahmen, Jan
    Eriksson, Anders R.
    Gabos, Balint
    Henriksson, Krister
    Hossain, Nafizal
    Ivanova, Svetlana
    Jansson, Anne-Helene
    Jensen, Tina J.
    Jerre, Anders
    Johansson, Henrik
    Klingstedt, Tomas
    Lepisto, Matti
    Lindsjo, Martin
    Mile, Irene
    Nikitidis, Grigorios
    Steele, John
    Tehler, Ulrika
    Wissler, Lisa
    Hanson, Thomas
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (20) : 8591 - 8605
  • [65] Niraparib: A Review in Ovarian Cancer
    Heo, Young-A
    Duggan, Sean T.
    [J]. TARGETED ONCOLOGY, 2018, 13 (04) : 533 - 539
  • [66] Phase II study of intravenous CI-958 in metastatic colorectal adenocarcinoma
    Hoff, PM
    Ellerton, JA
    Dakhil, SR
    Winn, RJ
    Abbruzzese, JL
    Pazdur, R
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (06): : 602 - 604
  • [67] BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: A phase II study group trial of the central European Society of Anticancer-Drug Research (CESAR)
    Hofheinz, RD
    Porta, C
    Hartung, G
    Santoro, A
    Hanauske, AR
    Kutz, K
    Stern, A
    Barbieri, P
    Verdi, E
    Hehlmann, R
    Hochhaus, A
    [J]. INVESTIGATIONAL NEW DRUGS, 2005, 23 (04) : 363 - 368
  • [68] Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor
    Hu, Huimin
    Mu, Quanhua
    Bao, Zhaoshi
    Chen, Yiyun
    Liu, Yanwei
    Chen, Jing
    Wang, Kuanyu
    Wang, Zheng
    Nam, Yoonhee
    Jiang, Biaobin
    Sa, Jason K.
    Cho, Hee-Jin
    Her, Nam-Gu
    Zhang, Chuanbao
    Zhao, Zheng
    Zhang, Ying
    Zeng, Fan
    Wu, Fan
    Kang, Xun
    Liu, Yuqing
    Qian, Zenghui
    Wang, Zhiliang
    Huang, Ruoyu
    Wang, Qiangwei
    Zhang, Wei
    Qiu, Xiaoguang
    Li, Wenbin
    Nam, Do-Hyun
    Fan, Xiaolong
    Wang, Jiguang
    Jiang, Tao
    [J]. CELL, 2018, 175 (06) : 1665 - +
  • [69] Structural Insights into the Induced-fit Inhibition of Fascin by a Small-Molecule Inhibitor
    Huang, Jianyun
    Dey, Raja
    Wang, Yufeng
    Jakoncic, Jean
    Kurinov, Igor
    Huang, Xin-Yun
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2018, 430 (09) : 1324 - 1335
  • [70] Nicotinic acetylcholine receptors: From basic science to therapeutics
    Hurst, Raymond
    Rollema, Hans
    Bertrand, Daniel
    [J]. PHARMACOLOGY & THERAPEUTICS, 2013, 137 (01) : 22 - 54